COYA — Coya Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1835022 ·
Last close
$3.02
Market Cap
$70.84M
52W High
$6.62
52W Low
$2.72
ADV30
170,209
Next earnings
2026-11-10
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 234,134 — -10,948,601 -10,617,741 39,317,729 35,802,136 5,749,383
Jun 2026 243,745 — -7,046,988 -6,638,260 47,308,078 43,181,002 4,032,067
Mar 2026 251,147 — -7,640,217 -7,206,990 53,271,099 50,724,643 4,300,739
Dec 2025 3,959,999 — -6,030,888 -5,708,542 49,950,245 46,822,786 6,922,015

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-21,826,758
Investing CF
$-1,558,502
Financing CF
$31,057,530
CapEx
$-23,240
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.18
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-86,426,268
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-31,666,694
Pretax Income TTM
$-30,168,444
Interest Exp TTM
—
Analysts
7

Yahoo Snapshot (yfinance, live)

Total Revenue
$4,689,025
EBITDA
$-29,842,930
Free Cash Flow
$-13,559,663
Enterprise Value
$37,620,932
Total Cash
$35,802,136
Total Debt
$0
Shares Out
23,457,849
Trailing EPS
$-1.39
Book Value
$1.43
ROE
-99.2%
ROA
-52.3%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 7,945,753 -22,555,225 -21,226,107 49,950,245 6,922,015 43,028,230 -10,739,301
Dec 2024 3,554,061 -17,249,711 -14,880,787 44,347,016 4,769,921 39,577,095 -10,288,822
Dec 2023 6,002,206 -7,903,349 -7,987,836 41,262,274 5,626,665 35,635,609 -11,188,811
Dec 2022 0 -9,811,939 -12,244,776 8,395,566 16,789,111 -8,393,545 -7,239,354
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$8,019,145
NetIncome TTM
$-21,669,623
OpCashFlow TTM
—
Assets (Latest)
$47,308,078
Forward EPS
$-2.02

Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)

max pain strike: $2.50 · spot: $3.09 · call volume: 6 · put volume: 221
Expected Move to 2027-02-19: ±$2.75 (89.00%) — implied range $0.34 – $5.84 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ZYBT Zhengye Biotechnology Holding Ltd $72.03M $1.52 —
VTVT vTv Therapeutics Inc. $69.36M $17.29 —
MNOV MEDICINOVA INC $68.65M $1.34 —
CING Cingulate Inc. $68.64M $4.72 —
GOSS Gossamer Bio, Inc. $67.52M $11.04 —

News headlines (Yahoo Finance, 1h cache)

Coya Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
2026-11-10 13:00 · Yahoo
Coya Therapeutics to Present Neurofilament Light Chain (NfL) Biomarker Stratification Methodology in the ALSTARS Trial to Minimize the Impact of Heterogeneity in ALS Clinical Trials at the 2026 Annual
2026-10-28 12:00 · Yahoo
Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS
2026-10-14 12:00 · Yahoo
Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare Conference
2026-10-13 12:00 · Yahoo
Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation
2026-09-08 12:00 · Yahoo
Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase
2026-06-08 12:00 · Yahoo
Coya Therapeutics secures FDA fast track status for COYA 302
2026-05-14 11:15 · Yahoo
Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease
2026-06-15 12:00 · Yahoo
Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
2026-10-05 12:00 · Yahoo
Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
2026-09-15 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.